相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1805
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Researchers found that individuals in Tübingen's type 2 diabetes risk cluster 5 continued to experience rising blood glucose and declining insulin secretion despite sustained 8% weight loss over nine years. - The study analyzed participants from the Tübingen Lifestyle Intervention Program (TULIP) who achieved substantial long-term weight loss through a two-year lifestyle program. - Severe insulin resistance linked to fatty liver disease appears to drive the persistently elevated diabetes risk in cluster 5 individuals, impairing pancreatic beta cell function. - Findings suggest diabetes prevention may need to become more personalized, with high-risk individuals requiring targeted treatments beyond lifestyle modification alone.
- A phase 1 trial of iTAC-XS15-CLL01, a personalized multipeptide T-cell activator, showed robust immune responses in 19 of 20 chronic lymphocytic leukemia patients receiving BTK inhibitor therapy. - The treatment demonstrated an acceptable safety profile with no grade 4 adverse events or treatment-related serious adverse events, with most side effects being local injection site reactions. - Sustained T-cell responses persisted at six months follow-up in 84% of patients, with 90% showing reduced CLL cell populations compared to baseline. - All patients remained alive with no disease progression during the study period, supporting further evaluation in phase 2 randomized trials.
- University Hospital Tübingen has initiated the first study site for the DEPECA-1 phase-2 trial, marking a significant milestone for advanced penile cancer treatment research. - The investigator-initiated trial will evaluate the combination of enfortumab vedotin and avelumab as first-line therapy for male patients with surgically incurable locally advanced or metastatic penile cancer. - Patient recruitment is expected to begin in December 2025, with the study sponsored by IKF and funded by Merck Group and Astellas Pharma. - The trial represents a promising therapeutic approach for a patient population with limited treatment options and poor life expectancy outcomes.
- An interdisciplinary research team involving the German Center for Infection Research has identified two antiviral drug candidates, phenformin and atpenin A5, effective against a wide range of RNA viruses through computer-aided modeling combined with laboratory validation. - Phenformin, a previously used diabetes medication, significantly reduced SARS-CoV-2 viral load in infected hamsters and inhibited dengue virus multiplication in cell cultures, offering potential for rapid clinical translation due to its established human safety profile. - The study demonstrates a novel computational approach that identifies metabolic processes essential for viral replication but not cellular survival, accelerating antiviral drug development for future pandemic preparedness.
